Clinical Trial Update: HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects [Phase 1]

View source ↗

Summary

Clinical trial update for HDM1002 tablets in overweight and obese adults; the Phase 1 study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• HDM1002 (HDM1002)

Snippet

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Conditions: Glucagon-Like Peptide-1 Receptor Agonists | Phase 1 | Status: NOT_YET_RECRUITING